WILMINGTON, MA--(Marketwire - Oct 25, 2011) - Implant Sciences Corporation (OTCQB: [ IMSC ]) (PINKSHEETS: [ IMSC ]), a high technology supplier of systems and sensors for homeland security markets, today announced the sale of additional units of its Quantum Sniffer™ QS-H150 handheld explosives trace detector to the Beijing Subway system, an existing customer in China.

The Beijing Subway is a modern system with 14 lines, all of which have been built in the past decade. With 172 stations, the Beijing Subway ranks fifth in the world for annual ridership and is the fourth longest in the world for track length. Having purchased Quantum Sniffers every year since 2008, the Beijing Subway now has over 200 QS-H150 portable explosives trace detectors in service.

"We are very pleased with the repeat business we have been able to obtain from our customers in China and around the world. Our distribution partners and sales team do an excellent job of demonstrating the QS-H150's suitability for a wide range of applications and environments. But the performance, quality, flexibility, and low cost of ownership of the product are what drive follow-on orders," stated Bruce Bower, Implant Sciences' Sr. Vice President, Sales and Marketing.

About the Quantum Sniffer™ QS-H150

The QS-H150 Quantum Sniffer is a hand-held explosives trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, improvised, and homemade explosives. The QS-H150 uses no radioactive materials and features a low-maintenance design that is self-calibrating and self-clearing, providing very high levels of operational availability.

About the Quantum Sniffer™ QS-B220

The QS-B220 Quantum Sniffer, introduced in May 2011, is a bench-top explosives and narcotics trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, improvised, or homemade explosives and narcotic substances. The QS-B220 continues the Implant Sciences tradition of freedom from radioactive materials, low total cost of ownership, and high operational availability.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 bench-top explosives and narcotics trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at [ www.implantsciences.com ].

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.